PubRank

Klaus Elenius

Author PubWeight™ 45.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004 2.47
2 Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005 1.93
3 Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006 1.85
4 High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 2014 1.79
5 ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. J Am Soc Nephrol 2011 1.61
6 ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002 1.58
7 Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008 1.57
8 Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 2005 1.53
9 Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A 2008 1.39
10 Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J 2003 1.38
11 Association of Wwox with ErbB4 in breast cancer. Cancer Res 2007 1.37
12 ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol 2009 1.28
13 Function of ERBB4 is determined by alternative splicing. Cell Cycle 2011 1.26
14 The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell 2006 1.23
15 Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 2003 1.23
16 Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J Biol Chem 2004 1.20
17 Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem 2008 1.11
18 Endothelial cell-matrix interactions. Microsc Res Tech 2003 1.09
19 Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia 2009 1.09
20 Cell death or survival promoted by alternative isoforms of ErbB4. Mol Biol Cell 2010 1.07
21 Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 2009 0.98
22 DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mol Cell Biol 2005 0.95
23 Potential of ErbB4 antibodies for cancer therapy. Future Oncol 2010 0.93
24 Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res 2007 0.92
25 Proteolytic processing of ErbB4 in breast cancer. PLoS One 2012 0.90
26 ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet 2013 0.90
27 Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling. J Biol Chem 2012 0.89
28 The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvasc Res 2009 0.89
29 ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta Oncol 2004 0.88
30 Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J Biol Chem 2012 0.87
31 CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol 2013 0.86
32 Mutated ERBB4: a novel drug target in metastatic melanoma? Pigment Cell Melanoma Res 2009 0.81
33 EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Expert Opin Emerg Drugs 2010 0.80
34 Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth. Exp Cell Res 2010 0.79
35 Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient. Mol Med 2007 0.79
36 ErbB targeted drugs and angiogenesis. Curr Vasc Pharmacol 2010 0.79
37 O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. Semin Thromb Hemost 2007 0.78
38 Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor. BMC Cell Biol 2009 0.77
39 ErbB4, a receptor tyrosine kinase, coordinates organization of the seminiferous tubules in the developing testis. Mol Endocrinol 2014 0.76
40 ErbB4 and its isoforms: patentable drug targets? Recent Pat DNA Gene Seq 2008 0.76
41 Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma. PLoS One 2012 0.75
42 Translation of a research-based genetic test on a rare syndrome into clinical service testing, with sotos syndrome as an example. Genet Test Mol Biomarkers 2012 0.75
43 Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. Radiother Oncol 2007 0.75